Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Travere Therapeutics Inc TVTX

Healthcare Biotechnology

Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for... see more

Add To Watchlist

Recent & Breaking News (NDAQ:TVTX)

Retrophin Completes Enrollment of Pivotal Phase 3 FORT Study of Fosmetpantotenate in PKAN

GlobeNewswire December 20, 2018

Retrophin to Present at the BMO Prescriptions for Success Healthcare Conference

GlobeNewswire November 28, 2018

Report: Developing Opportunities within Liberty TripAdvisor, Chanticleer, Retrophin, Menlo Therapeutics, Shire plc, and Matthews International — Future Expectations, Projections Moving into 2018

GlobeNewswire November 28, 2018

Retrophin Announces U.S. FDA Acceptance of NDA Filing for the New Formulation of Thiola® (tiopronin) in the Treatment of Cystinuria

GlobeNewswire November 12, 2018

Retrophin to Present at the Jefferies 2018 London Healthcare Conference

GlobeNewswire November 7, 2018

Retrophin Reports Third Quarter 2018 Financial Results

GlobeNewswire November 1, 2018

Robbins Arroyo LLP Is Investigating the Officers and Directors of Retrophin, Inc. (RTRX) on Behalf of Shareholders

Business Wire October 29, 2018

Retrophin Reports Positive Long-Term Data from Open-Label Extension of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis

GlobeNewswire October 26, 2018

Retrophin Announces Publication of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis in the Journal of the American Society of Nephrology

GlobeNewswire October 25, 2018

Retrophin to Report Third Quarter 2018 Financial Results

GlobeNewswire October 18, 2018

Retrophin to Present Long-Term Data from Phase 2 DUET Study of Sparsentan in FSGS at ASN Kidney Week 2018

GlobeNewswire October 5, 2018

Retrophin to Highlight Fosmetpantotenate Program for PKAN at Upcoming Medical Congresses

GlobeNewswire October 3, 2018

Retrophin Announces Upcoming Presentations at the 15th International Symposium on IgA Nephropathy

GlobeNewswire September 27, 2018

Retrophin to Present at Upcoming Investor Conferences

GlobeNewswire September 17, 2018

Retrophin Prices Upsized $240 Million Convertible Senior Notes Offering

GlobeNewswire September 5, 2018

Retrophin Announces Proposed Convertible Senior Notes Offering

GlobeNewswire September 4, 2018

New Research Coverage Highlights pdvWireless, Fortuna Silver Mines, Nordic American Tankers, Amarin, Himax Technologies, and Retrophin — Consolidated Revenues, Company Growth, and Expectations for 2018

GlobeNewswire August 21, 2018

Retrophin Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer

GlobeNewswire July 30, 2018

Retrophin Reports Second Quarter 2018 Financial Results and Announces CEO Transition Plan

GlobeNewswire July 26, 2018

Retrophin to Report Second Quarter 2018 Financial Results

GlobeNewswire July 12, 2018